Last week, we published the news that Amplio Spine, LLC had signed a Letter of Intent to acquire the FDA-cleared KeyLift™ Expandable Interlaminar Stabilization System from FloSpine, LLC. This announcement brings interspinous and interlaminar implants back into focus. For that reason, we have updated our overview of this product category and its market, looking not only at KeyLift™ itself, but also at the broader role these devices play between decompression, stabilization and fusion in the treatment of selected lumbar spine conditions.
Back in the early 2000s, interspinous devices emerged as a less invasive alternative to traditional instrumentation, with the potential for lower risk and faster recovery. Between 2005 and 2012, many devices of this type entered the market, and most major spine companies added one to their portfolios, including X-STOP® from Medtronic, Coflex® from Paradigm Spine, DIAM™ from Medtronic, and Wallis® from Zimmer Biomet. Their use expanded rapidly, perhaps in some cases beyond the strictest indications, driven by their simplicity and the promise of immediate clinical results.
However, the story of interspinous devices also became a cautionary tale: enthusiasm without evidence can backfire.
Why the Surge?
For many patients, these devices represented a last minimally invasive option to avoid dreaded spinal fusion. They also offered multiple advantages for both patients and surgeons:
- Simpler and faster surgical techniques
- Partial preservation of segmental motion
- Reduced complications associated with fusion
- Favorable reimbursement in private healthcare systems
The combination of demand for minimally invasive surgery and aggressive marketing created a market worth hundreds of millions of dollars in less than a decade. At spine conferences, interspinous devices were showcased as the future of lumbar surgery.
The Market
The interspinous and interlaminar implants represent a niche spine segment, but not an irrelevant one. Market estimates vary but most conservative figures place the global interspinous spacers market somewhere around US$80–100 million in 2024–2025 and projects a rise to approximately US$116 million by 2030.
This environment led to the introduction of numerous devices. At one point, more than 50 different models were available, though most have now disappeared.
The interspinous and interlaminar category should not be viewed as a single, uniform market. It includes different device philosophies, from dynamic stabilization after decompression to indirect decompression spacers and posterior non-pedicle fixation systems intended to support fusion.
Why the Decline?
Overindication and use outside strict indications led to long-term results that were not good enough. Clinical studies indicate that reoperation rates reached 30–38% in certain patient groups over 2–5 years. Complications such as implant migration, spinous process fractures, and persistent or recurrent symptoms were also documented.
Faced with this situation, regulatory agencies reacted, and in the US the FDA restricted the indications and required more clinical evidence. Without doubt, this is a useful lesson for the spine industry of how a well-designed implant for specific indications can lose legitimacy through overuse and commercial pressure.
A Second Chance: New-Generation Devices
Despite past setbacks, interspinous systems have not disappeared. Over the last decade, manufacturers have attempted technical and conceptual reinvention to correct previous mistakes.
Improved Design and Materials: New models incorporate porous titanium alloys or bioactive PEEK for better integration and reduced migration risk. They feature expandable or modular geometries tailored to individual anatomy, along with interlaminar anchoring systems for greater stability.
More Precise Clinical Selection: The key today is to implant only in appropriate patients. The best outcomes are seen in:
- Mild to moderate lumbar stenosis without significant instability
- Patients with neurogenic claudication are unresponsive to conservative treatments
- Cases where segmental mobility preservation is desired
Stronger Evidence and Regulatory Oversight: New devices must pass multicenter clinical trials with follow-up beyond five years and demonstrate cost-effectiveness against existing alternatives. International clinical registries now allow real-time monitoring of complications and revision rates, reducing the opacity that characterized first-generation devices.
What are the FDA-Approved Interspinous Systems?
Several systems are FDA-approved, though indications and scope vary:
- Superion® Interspinous Spacer (VertiFlex/Boston Scientific): PMA-approved for moderate lumbar stenosis
- Coflex® Interlaminar Technology (Paradigm Spine): dynamic stabilization post-decompression in one or two lumbar levels
- X-Stop® (Medtronic): approved in 2005 for older patients with neurogenic claudication, later withdrawn
Interspinous fusion systems, such as Inspan™ Spinous Process Plate System and Axle™-PEEK Interspinous Fusion System and KeyLift™ Expandable Interlaminar Stabilization System, which received FDA 510(k) clearance in late 2023 under K232484. The FDA distinguishes between dynamic decompression “spacers” and fixation/fusion devices, with different regulations, goals, and levels of clinical evidence.
The Return of Interspinous Devices: A More Selective Market
Today, interspinous and interlaminar devices are back, but the situation is very different from the enthusiasm of the early 2000s. This new generation is trying to correct the weaknesses that caused these devices to lose legitimacy. Today, indications, patient selection, demonstration of clinical value and, above all, avoidance of overuse are what matter. Therefore, rather than a simple comeback, we should speak of an evolution.
These implants will continue to represent a niche market, but when used appropriately, they can be useful for rigorously selected patients. Their opportunity is not so much to promise more than they can deliver, but to show that the concept can be supported by clinical evidence.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.